HAGE, a cancer/testis antigen with potential for melanoma immunotherapy: identification of several MHC class I/II HAGE-derived immunogenic peptides. - Institut Pasteur Access content directly
Journal Articles Cancer Immunology, Immunotherapy Year : 2007

HAGE, a cancer/testis antigen with potential for melanoma immunotherapy: identification of several MHC class I/II HAGE-derived immunogenic peptides.

Abstract

There remains a need to identify novel epitopes of potential tumour target antigens for use in immunotherapy of cancer. Here, several melanoma tissues and cell lines but not normal tissues were found to overexpress the cancer-testis antigen HAGE at the mRNA and protein level. We identified a HAGE-derived 15-mer peptide containing a shorter predicted MHC class I-binding sequence within a class II-binding sequence. However, only the longer peptide was found to be both endogenously processed and immunogenic for T cells in transgenic mice in vivo, as well as for human T cells in vitro. A different class I-binding peptide, not contained within a longer class II sequence, was subsequently found to be both immunogenic and endogenously processed in transgenic mice, as was a second class II epitope. These novel HAGE-derived epitopes may contribute to the range of immunotherapeutic targets for use in cancer vaccination programs.

Domains

Immunology

Dates and versions

pasteur-00167484 , version 1 (21-08-2007)

Identifiers

Cite

Morgan Mathieu, Ashley Knights, Graham Pawelec, Catherine Riley, Dorothee Wernet, et al.. HAGE, a cancer/testis antigen with potential for melanoma immunotherapy: identification of several MHC class I/II HAGE-derived immunogenic peptides.. Cancer Immunology, Immunotherapy, 2007, epub ahead of print. ⟨10.1007/s00262-007-0331-2⟩. ⟨pasteur-00167484⟩

Collections

PASTEUR
86 View
0 Download

Altmetric

Share

Gmail Facebook X LinkedIn More